Form 4: REGENXBIO Director David C. Stump Receives Significant Equity Awards

REGENXBIO Inc. Director David C. Stump was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• REGENXBIO Inc. Director David C. Stump reported the acquisition of 7,768 shares of common stock underlying a time-based restricted stock unit (RSU) award.
• These RSUs were granted at a price of $0.00 and will vest 100% on May 1, 2026, contingent upon Mr. Stump's continuous service to the Issuer.
• Following this transaction, Mr. Stump beneficially owns 19,054 shares of common stock.
• Additionally, Mr. Stump acquired 39,815 stock options with an exercise price of $8.85 per share, also granted at a price of $0.00.
• These stock options will begin vesting on May 30, 2025, in 12 equal monthly installments, subject to his continuous service, and have an expiration date of May 30, 2035.
• After this transaction, Mr. Stump beneficially owns 39,815 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as the document reports equity awards to a director, which aligns their interests with shareholders and is a standard practice for incentivizing long-term commitment. It does not contain any negative financial or operational news.

Positives

• The grant of restricted stock units and stock options to Director David C. Stump aligns his financial interests directly with the long-term performance and shareholder value of REGENXBIO Inc.
• Equity compensation is a standard practice to attract and retain experienced directors, signaling commitment to corporate governance and strategic oversight.

Future Outlook

The equity awards, specifically the restricted stock units and stock options, are subject to future vesting schedules contingent on the director's continuous service, indicating an expectation of ongoing commitment and contribution to the company's future performance.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a common practice across the biotechnology and pharmaceutical industries. This compensation structure is widely used to incentivize long-term commitment, align leadership interests with shareholder returns, and attract top talent in a competitive sector.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard component of director remuneration in publicly traded companies, particularly within the biotech sector, to align director incentives with long-term shareholder value.
• The vesting schedules (time-based for RSUs and monthly installments for options) are typical mechanisms used to ensure continued service and commitment from board members.
• While specific award sizes vary by company size, performance, and individual director responsibilities, the structure of these awards is consistent with common corporate governance practices in the industry.

Related Party Transactions

• The transaction involves the grant of equity awards (restricted stock units and stock options) from REGENXBIO Inc. to David C. Stump, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.
• Employees: While not directly impacting general employees, the compensation structure for leadership can influence overall company culture and compensation philosophy.
• Director (David C. Stump): Receives significant equity compensation, incentivizing his continued service and performance.

Next Steps

• The restricted stock units are scheduled to vest on May 1, 2026, subject to continuous service.
• The stock options will vest in 12 equal monthly installments following May 30, 2025, subject to continuous service.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership